AU5716898A - Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease - Google Patents

Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease

Info

Publication number
AU5716898A
AU5716898A AU57168/98A AU5716898A AU5716898A AU 5716898 A AU5716898 A AU 5716898A AU 57168/98 A AU57168/98 A AU 57168/98A AU 5716898 A AU5716898 A AU 5716898A AU 5716898 A AU5716898 A AU 5716898A
Authority
AU
Australia
Prior art keywords
alzheimer
disease
treatment
combination
acetylcholinesterase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU57168/98A
Inventor
Michael James Callahan
Roy Douville Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU5716898A publication Critical patent/AU5716898A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU57168/98A 1997-01-08 1997-12-29 Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease Abandoned AU5716898A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3405997P 1997-01-08 1997-01-08
US60034059 1997-01-08
US6588697P 1997-11-17 1997-11-17
US60065886 1997-11-17
PCT/US1997/023792 WO1998030243A1 (en) 1997-01-08 1997-12-29 Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
AU5716898A true AU5716898A (en) 1998-08-03

Family

ID=26710494

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57168/98A Abandoned AU5716898A (en) 1997-01-08 1997-12-29 Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease

Country Status (4)

Country Link
AU (1) AU5716898A (en)
CO (1) CO5011095A1 (en)
HR (1) HRP980006A2 (en)
WO (1) WO1998030243A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
GB9807931D0 (en) * 1998-04-15 1998-06-10 Medical Res Council Improvements in or relating to protease inhibitors
GB9815383D0 (en) * 1998-07-15 1998-09-16 Smithkline Beecham Plc Novel method of treatment
IE990286A1 (en) * 1999-04-07 2000-11-01 Malope Company Ltd Diagnosis of irritable bowel syndrome based on demonstrated central cholinergic supersensitivity.
US20030144255A1 (en) * 2000-03-06 2003-07-31 Bain Allen I Compositions for prevention and treatment of dementia
DE10106971A1 (en) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Drug formulation containing a muscarinic agonist
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
JP5523107B2 (en) 2006-11-30 2014-06-18 プロビオドルグ エージー Novel inhibitors of glutaminyl cyclase
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP2456868A4 (en) 2009-07-22 2013-11-06 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
AU2010294214B2 (en) 2009-09-11 2015-05-07 Vivoryon Therapeutics N.V. Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CN109662964A (en) 2010-02-09 2019-04-23 约翰斯.霍普金斯大学 For improving the method and composition of cognitive function
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
KR101790806B1 (en) 2010-03-10 2017-11-20 프로비오드룩 아게 Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
DK2686313T3 (en) 2011-03-16 2016-05-02 Probiodrug Ag Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
WO2015163485A1 (en) 2014-04-23 2015-10-29 Takeda Pharmaceutical Company Limited Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease
JP6899043B2 (en) 2015-05-22 2021-07-07 エージンバイオ， インコーポレイテッド Sustained release pharmaceutical composition of levetiracetam
UA121503C2 (en) 2015-06-26 2020-06-10 Такеда Фармасьютікал Компані Лімітед 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
JP6787913B2 (en) 2015-10-20 2020-11-18 武田薬品工業株式会社 Heterocyclic compound
BR112019023569A2 (en) * 2017-06-01 2020-06-02 Eisai R&D Management Co., Ltd. THERAPEUTIC AGENT OF DEMENTIA COMBINING PIRAZOLOQUINOLINE AND DONEPEZILA DERIVATIVES
DK3461819T3 (en) 2017-09-29 2020-08-10 Probiodrug Ag GLUTAMINYL CYCLASE INHIBITORS
BR112021005802B1 (en) 2018-09-28 2022-02-15 Karuna Therapeutics, Inc ORAL PHARMACEUTICAL COMPOSITION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
US4647580A (en) * 1985-07-18 1987-03-03 Syntex (U.S.A.) Inc. Treatment of Alzheimer's disease
EP0408650A1 (en) * 1988-04-08 1991-01-23 Massachusetts Institute Of Technology Method and composition for treating neurological disorders
DE4136288A1 (en) * 1991-11-04 1993-05-06 Troponwerke Gmbh & Co Kg, 5000 Koeln, De COMBINATION OF CALCIUM ANTAGONISTS WITH CHOLINESTERASE INHIBITORS
WO1993013083A1 (en) * 1991-12-31 1993-07-08 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
US5744476A (en) * 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia

Also Published As

Publication number Publication date
WO1998030243A1 (en) 1998-07-16
HRP980006A2 (en) 1998-10-31
CO5011095A1 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
AU5716898A (en) Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
AU1407399A (en) Treatment for alzheimer's disease
GB2367060B (en) Alzheimer's disease secretase,app substrates therefor,and uses therefor
EP1007048A4 (en) Identification of agents for use in the treatment of alzheimer's disease
AU4078997A (en) Cholinesterase inhibitors for treatment of parkinson's disease
AP2001002102A0 (en) Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas
AU4775797A (en) Process for the determination of app secretase modulators and the use thereof as agents in the treatment of alzheimer's disease
IL119417A0 (en) Drug for Parkinson's disease
IL127146A0 (en) Transdermal propentofylline compositions for the treatment of alzheimer's disease
AU4078900A (en) Methods for tracking the progression of alzheimer's disease and identifying treatments using transgenic mice
AU6035898A (en) Table of contents caching method for enhancing access to cd-rom's and the like
AU2418499A (en) Org-5222 in the treatment of depression
AU5053296A (en) Pharmaceutical agents for the treatment of Alzheimer's disease
AU1405899A (en) Treatment for alzheimer's disease
EP1152762B8 (en) Use of desoxypeganine in the treatment of alzheimer's dementia
AU4707101A (en) Method and system for online third party referral system customized to the purchaser's needs
AU6786898A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU6786598A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
ZA98118B (en) Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
AU6786798A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU8580598A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU5495398A (en) Idebenone containing combination agent for treating alzheimer's disease
AU6786698A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU2215099A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
AU2002301084A1 (en) Identification of agents for use in the treatment of alzheimer's disease